国药现代(600420) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥3,332,135,975.28, representing an increase of 8.26% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was ¥201,521,805.81, a decrease of 1.85% year-on-year, while the year-to-date net profit decreased by 32.48% to ¥426,372,120.55[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥161,261,302.61, down 3.41% year-on-year, with a year-to-date decrease of 38.39% to ¥356,018,230.66[5]. - The basic earnings per share for Q3 2022 was ¥0.1963, reflecting a decrease of 32.48% compared to the same period last year[5]. - The diluted earnings per share for Q3 2022 was ¥0.1732, down 30.90% year-on-year[7]. - The weighted average return on equity for Q3 2022 was 2.26%, a decrease of 0.14 percentage points compared to the previous year[7]. - Total operating revenue for the first three quarters of 2022 was CNY 9,719,160,020.44, a decrease of 9.3% compared to CNY 10,710,170,799.63 in the same period of 2021[26]. - Net profit for the first three quarters of 2022 was CNY 604,173,833.75, a decline of 24.4% from CNY 799,702,644.46 in the same period of 2021[29]. - Basic earnings per share for the first three quarters of 2022 were CNY 0.4152, down from CNY 0.6149 in the same period of 2021[31]. Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥18,500,232,428.08, a decrease of 2.99% compared to the end of the previous year[7]. - As of September 30, 2022, total assets amounted to ¥18,500,232,428.08, a decrease from ¥19,069,961,392.45 as of December 31, 2021, reflecting a decline of approximately 2.99%[24]. - Total current assets were reported at ¥10,590,812,386.23, down from ¥10,886,446,261.52, indicating a decrease of about 2.71%[18]. - Total liabilities decreased to ¥7,792,999,911.35 from ¥8,700,102,902.92, reflecting a reduction of about 10.43%[22]. - The total liabilities decreased to ¥4,457,324,838.87 as of September 30, 2022, from ¥4,685,533,578.22 at the end of 2021, representing a reduction of 4.9%[44]. - The total equity increased to ¥7,898,062,555.98 as of September 30, 2022, compared to ¥7,383,207,177.95 at the end of 2021, reflecting a growth of 7%[44]. Cash Flow - The net cash flow from operating activities for the year-to-date period increased by 43.19% to ¥1,965,774,395.17[11]. - Cash flow from operating activities was CNY 8,912,017,188.80 for the first three quarters of 2022, a decrease from CNY 9,885,981,372.64 in the same period of 2021[33]. - Net cash flow from operating activities for the first three quarters of 2022 was CNY 1,965,774,395.17, an increase of 43.3% compared to CNY 1,372,864,799.01 in the same period of 2021[35]. - The cash flow from operating activities for the first three quarters of 2022 was ¥846,998,456.75, a substantial increase from ¥157,063,234.34 in the same period of 2021[54]. Expenses - Total operating costs for the first three quarters of 2022 were CNY 9,013,362,094.64, down 8.3% from CNY 9,829,243,735.14 in the previous year[26]. - Research and development expenses for the first three quarters of 2022 amounted to CNY 360,086,744.11, a slight decrease of 6.8% compared to CNY 386,254,592.42 in 2021[26]. - Sales expenses decreased to CNY 2,189,914,277.14 in the first three quarters of 2022, down 20.6% from CNY 2,759,870,569.86 in the same period of 2021[26]. - The company reported a significant improvement in credit impairment losses, with a loss of CNY 4,784,358.27 in 2022 compared to a loss of CNY 29,837,513.78 in 2021[29]. - The company's sales expenses surged to ¥496,227,887.10 in the first three quarters of 2022, compared to ¥113,917,294.89 in the same period of 2021, reflecting a significant increase of 336.5%[46]. Cash Management - The company's cash and cash equivalents increased to ¥4,382,038,580.45 from ¥4,284,240,287.88, showing a growth of approximately 2.29%[17]. - Cash and cash equivalents at the end of the reporting period were CNY 4,144,908,326.08, up from CNY 3,778,658,665.42 at the end of 2021, marking an increase of 9.7%[36]. - The company reported a cash decrease of approximately -$2.22 million in 2022, compared to a larger decrease of -$114.47 million in 2021, indicating an improvement in cash management[55]. - The company’s cash flow from investment activities showed a positive turnaround, moving from a negative cash flow in 2021 to a positive cash flow in 2022[55]. Market Conditions - The company attributed the decline in net profit to factors such as the resurgence of COVID-19, market competition, and rising prices of raw materials and fuels[9].